A randomized trial of five years of letrozole versus placebo after aromatase inhibitor-based therapy: NRG Oncology/NSABP B-42

BACKGROUND: The optimal duration of extended therapy with aromatase inhibitors in patients with postmenopausal breast cancer is unknown. In the NSABP B-42 study, we aimed to determine whether extended letrozole treatment improves disease-free survival after 5 years of aromatase inhibitor-based thera...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Oncol
Main Authors: Mamounas, Eleftherios P., Bandos, Hanna, Lembersky, Barry C., Jeong, Jong-Hyeon, Geyer, Charles E., Rastogi, Priya, Fehrenbacher, Louis, Graham, Mark L., Chia, Stephen K., Brufsky, Adam M., Walshe, Janice M., Soori, Gamini S., Dakhil, Shaker R., Seay, Thomas E., Wade, James L., McCarron, Edward C., Paik, Soonmyung, Swain, Sandra M., Lawrence Wickerham, D., Wolmark, Norman
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6691732/
https://ncbi.nlm.nih.gov/pubmed/30509771
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(18)30621-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados